Session 124 - CROI 2008

Home

Session 124 Poster Abstracts
ART: Novel Approaches II
Tuesday, 1-4 pm
Room: Hall A

743	Ritonaivr-, Lopinavir-, and Efavirenz-containing Nanoparticles: in vitro Release of ART Chris Destache*, T Belgum, G Elsasser, K Christensen, and A Shibata Creighton Univ, Omaha, NE, US
744	HIV-1 Inhibition with Multi-valent Gold Nanoparticles Mary Catherine Bowman*¹, E Ballard², C Akerson², J D'Antonio², D Feldheim³, C Melander², and D Margolis¹ ¹Univ of North Carolina at Chapel Hill, US; ²North Carolina State Univ, Raleigh, US; and ³Univ of Colorado, Boulder, US
745	Anti-retroviral Nanoformulations for HIV-1-associated Cognitive Impairments Huanyu Dou*¹, C Grotepas¹, M Boska¹, C Destache², B Rabinow³, and H Gendelman¹ ¹Univ of Nebraska Med Ctr, Omaha, US; ²Creighton Univ Scho of Pharmacy and Hlth Professions, Omaha, NE, US; and ³Baxter Hlthcare Corp, Round Lake, IL, US
746	The Non-peptidic Carbohydrate-binding Pradimycin Antibiotics Inhibit HIV Infection, Viral Capture by DC-SIGN, and Viral Transmission and thus May Qualify as Potential Microbicide Candidate Drugs J Balzarini¹, K Francois¹, D Huskens¹, J Auwerx¹, K Van Laethem¹, Y Igarashi², T Oki³, and Dominique Schols*¹ ¹Rega Inst for Med Res, KULeuven, Belgium; ²Biotech Res Ctr, Toyama Prefectural Univ, Japan; and ³Keck Sch of Med, Univ of Southern California, Los Angeles, US
747	Carbohydrate-binding Agents Inhibit HIV-1 Infection of Human Primary Monocyte-derived Macrophages and Prevent MDM-directed Viral Capture and Subsequent Transmission to CD4⁺ T Lymphocytes Michela Pollicita*¹, D Schols², S Aquaro³, W Peumans⁴, E Van Damme⁴, C Perno¹, and J Balzarini² ¹Univ of Tor Vergata, Rome, Italy; ²Rega Inst for Med Res, KULeuven, Belgium; ³Univ of Calabria, Rende, Italy; and ⁴Ghent Univ, Belgium
748	CD7-specific Single Chain Antibody-mediated Delivery of siRNA to T Cells Inhibits HIV Replication in a Humanized Mouse Model Priti Kumar*¹, H Ban², S Kim¹, M Peipp³, G Fey³, L Schultz⁴, N Manjunath¹, S Lee², and P Shankar¹ ¹Immune Disease Inst, Boston, MA, US; ²Hanyang Univ, Seoul, Korea; ³Univ of Erlangen, Germany; and ⁴Jackson Lab, Bar Harbor, ME, US
749	Protein Phosphatase-1 as a New Target for Anti-HIV-1 Therapeutics T Ammosova¹, D Kovalskyy², V Yedavalli³, V Gordeuk¹, K T Jeang³, and Sergei Nekhai*¹ ¹Howard Univ, Washington, DC,US; ²Natl Taras Shevchenko Univ, Kiev, Ukraine; and ³NIAID, NIH, Bethesda, MD, US
750	Anti-HIV Activity of Aprepitant and Synergistic Interactions with Other Antiretrovirals Mark Manak*¹, D Moshkoff¹, L Nguyen¹, S Dryga¹, J Lathey², and S Douglas³ ¹SeraCare Life Sci, Inc, Gaithersburg, MA, US; ²Sanofi Pasteur, Swiftwater, PA, US; and ³Children`s Hosp Philadelphia, PA, US
751	A Novel Inhibitor of the HIV-1 Vpu Protein Can Inhibit the Replication of SHIV in a CD4⁺ T Cell Line Sarah Hill*¹, C Luscombe², J Wilkinson², G Ewart², and E Stephens¹ ¹Univ of Kansas Med Ctr, Kansas City, US and ²Biotron Ltd
752	Evaluation of the Lymphocyte Trafficking Drug FTY720 in SHIV-infected Rhesus Macaques Ellen Kersh*¹, M Premenko-Lanier², W Luo¹, D Adams¹, J Mitchell¹, G Garcia-Lerma¹, S Butera¹, T Folks¹, R Otten¹, and J Altman² ¹CDC, Atlanta, GA, US and ²Emory Vaccine Ctr, Atlanta, GA, US
753a	Lentiviral Delivered VRX496 Long Antisense Sequences Exerts Molecular Pressure on HIV-1 in Human Subjects Vladimir Lukashov*¹, M Quinones-Mateu², G McGarrity³, T Rebello³, and L Humeau³ ¹Academic Med Ctr, Amsterdam, The Netherlands; ²Diagnostic Hybrids Inc, Athens, OH, US; and ³VIRxSYS Corp, Gaithersburg, MD, US
753b	Dose Response Curve Slope Sets Class-specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen*¹, S Peterson¹, A Sedaghat¹, M McMahon¹, M Callender¹, H Zhang¹, Y Zhou¹, K Anderson², E Acosta³, and R Siliciano^1,4 ¹Johns Hopkins Univ Sch of Med, Baltimore, MD, US; ²Yale Univ Sch of Med, New Haven, CT, US; ³Univ of Alabama at Birmingham Sch of Med, US; and ⁴Howard Hughes Med Inst, Baltimore, MD, US